Executive interview – Onxeo

Executive interview – Onxeo

Onxeo is focused on cancer indications specialising in epigenetics and DNA break repair inhibition. Beleodaq, a HDAC inhibitor, is approved for PTCL in the US and partnered with Spectrum Pharmaceuticals. AsiDNA, a novel DNA break repair inhibitor from Onxeo’s platON platform, is expected to enter Phase I in 2018.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free